Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Liabilities: 2021-2024

Historic Total Liabilities for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to $109.5 million.

  • Krystal Biotech's Total Liabilities rose 5.96% to $102.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.2 million, marking a year-over-year increase of 5.96%. This contributed to the annual value of $109.5 million for FY2024, which is 175.62% up from last year.
  • As of FY2024, Krystal Biotech's Total Liabilities stood at $109.5 million, which was up 175.62% from $39.7 million recorded in FY2023.
  • In the past 5 years, Krystal Biotech's Total Liabilities registered a high of $109.5 million during FY2024, and its lowest value of $32.7 million during FY2021.
  • In the last 3 years, Krystal Biotech's Total Liabilities had a median value of $39.7 million in 2023 and averaged $61.8 million.
  • Data for Krystal Biotech's Total Liabilities shows a peak YoY surged of 175.62% (in 2024) over the last 5 years.
  • Yearly analysis of 4 years shows Krystal Biotech's Total Liabilities stood at $32.7 million in 2021, then rose by 10.70% to $36.2 million in 2022, then grew by 9.65% to $39.7 million in 2023, then skyrocketed by 175.62% to $109.5 million in 2024.